Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Baruch S. Blumberg Institute Honors Six Scientists for Life-Saving Research
  • USA - English


News provided by

Furia Rubel Communications, Inc.

Nov 02, 2015, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Baruch S. Blumberg Institute
Baruch S. Blumberg Institute

DOYLESTOWN, Pa. (PRWEB) November 02, 2015 -- Six scientists associated with the Baruch S. Blumberg Institute will have a permanent place of honor at its research center near Philadelphia for significantly advancing the treatment of such debilitating diseases as HIV, epilepsy and hepatitis C infection.

The scientists immortalized on this Wall of Fame have made enormous contributions to the field of medicine and to the relief of human suffering.

Post this

The Baruch S. Blumberg Institute, the research arm of the Hepatitis B Foundation, has unveiled a Drug Inventors Wall of Fame to recognize the six outstanding scientists whose drug discoveries, made prior to their arrival at the institute’s research center, have been approved by the U.S. Food and Drug Administration (FDA) for human use. The Drug Inventors Wall of Fame was unveiled during a ceremony on Oct. 20, 2015. Each of the six scientists now is either an adjunct professor with the Blumberg Institute and/or working at start-up companies headquartered at the research center.

“The scientists immortalized on this Wall of Fame have made enormous contributions to the field of medicine and to the relief of human suffering,” said Dr. Timothy Block, president and co-founder of the Baruch S. Blumberg Institute and the Hepatitis B Foundation. “The Blumberg Institute is proud to provide an environment in which scientists can be recognized and appreciated by the society that they have served so well with their commitment to life-changing research.”

Drug development is a notoriously slow, expensive process. It can take 10 to 15 years or longer to discover a drug, and can cost upwards of $1 billion.

“The path of a scientist often is a lonely one. For every drug that is approved, there are dozens if not hundreds of failures and dead ends. Researchers remain focused on their work, however, because they know that one day, they may be able to cure disease or ease suffering,” said Wayne Yetter, founding CEO of AstraMerck and former CEO of Novartis Pharmaceuticals Corp. and a member of the Hepatitis B Foundation’s Board of Directors. “Pausing to celebrate the achievements of these scientists reminds us all how vital the process of discovery and innovation is both to boosting our economy and improving quality of life for all of us.”

The six inaugural inductees to the Baruch S. Blumberg Institute Wall of Fame are:

Hank Breslin, M.S. Now Head of Medicinal Chemistry for Atrin Pharmaceuticals, Breslin is the co-discoverer of eluxadoline (Viberzi®), a treatment for irritable bowel syndrome with diarrhea. During his 25-year career at Johnson & Johnson, Breslin designed the enterology chemistry program and led the team whose research efforts culminated in the development of eluxadoline. The drug was approved by the FDA earlier this year. He lives in Lansdale, Pennsylvania.

Bruce Dorsey, Ph.D. Now Vice President of Chemistry at Arbutus Biopharma, Dr. Dorsey began his career at Merck & Co. where his work led to the discovery of indinavir sulfate (Crixivan™), an HIV protease inhibitor launched by Merck in 1996. The achievement led to national and international recognition for Dorsey, with several awards, most recently the 2007 European Inventor of the Year. Dorsey has co-authored 62 publications in chemistry and drug discovery and is a co-inventor on 41 patents and patent applications. He lives in Ambler, Pennsylvania.

Patrick Y. Lam, Ph.D. Dr. Lam is a co-discoverer of apixaban (Eliquis®), which was approved by the FDA in 2012 for use as an anticoagulant. Already internationally known as the co-discoverer of the Chan-Lam Coupling Reaction, Lam led the research team that was responsible for the discovery of apixaban while a director at Bristol-Myers Squibb. Now an independent consultant, Lam is an inventor on 36 patents and patent applications. He lives in Chadds Ford, Pennsylvania.

Bruce E. Maryanoff, Ph.D. A Distinguished Professor at the Baruch S. Blumberg Institute and Advisor to the Pennsylvania Drug Discovery Institute, Dr. Maryanoff is the discoverer of topiramate (Topamax®), a treatment for epilepsy and migraine headaches that the FDA approved for sale in 1996. Dr. Maryanoff has published 278 scientific papers and is an inventor on 100 U.S. patents. He retired in 2010 from Johnson & Johnson after 36 years in the medicinal chemistry field. He lives in New Hope, Pennsylvania.

Stacy W. Remiszewski, Ph.D. Dr. Remiszewski is the co-inventor of panobinostat (Farydak®), which the FDA approved in February 2015 for the treatment of multiple myeloma. Now Head of Chemistry at FORGE Life Science, Remiszewski led the team that discovered Farydak while he was with the Novartis Institutes for Biomedical Research. A research veteran with more than 20 years of experience, he is a co-inventor on 30 U.S. patents. He lives in Washington Township, New Jersey.

Michael J. Sofia, Ph.D. Dr. Sofia is the inventor of sofosbuvir (Sovaldi®), the revolutionary cure for hepatitis C infection approved by the FDA in 2013, and the sofosbuvir/ledipasvir combination (Harvoni®) approved in 2014. Sofia invented sofosbuvir while at Pharmasset Inc., and, after Pharmasset was acquired by Gilead Sciences in 2011, went on to found a new biopharma company. He now is Chief Scientific Officer at Arbutus Biopharma, which is dedicated to discovering, developing and commercializing a cure for chronic hepatitis B infection. He has authored more than 100 publications and is an inventor on more than 47 U.S. patents. He lives in Buckingham, Pennsylvania.

About the Baruch S. Blumberg Institute: The Baruch S. Blumberg Institute was established by the Hepatitis B Foundation as an independent, nonprofit research institute to fulfill its research mission and to conduct discovery research and nurture translational biotechnology in an environment conducive to interaction, collaboration and focus. The research center was renamed in 2013 to honor Baruch S. Blumberg who won the Nobel Prize for his discovery of the hepatitis B virus. To learn more, visit http://www.blumberginstitute.org.

Sarah Larson, Furia Rubel Communications, Inc., http://www.furiarubel.com, +1 (215) 340-0480, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.